Transine Therapeutics is a private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. Transine® pioneering technology is expected to offer an entirely unique mechanism of action for currently hard-to-treat diseases by massively extending the druggable proteome, enabling it to address diseases which have been beyond the reach of small molecules, conventional biologics or gene therapies.
Location: United Kingdom, England, Cambridge
Employees: 11-50
Total raised: $30.15M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | SV Health ... | svhealthin... |
| 06.06.2022 | Epidarex C... | epidarex.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 31.05.2022 | Seed | $17.25M | - |
| 02.06.2021 | Seed | $12.9M | Dementia D... |
Mentions in press and media 8
| Date | Title | Description |
| 31.05.2022 | Transine Therapeutics Closes £13.7M in Seed Funding | Transine Therapeutics, a Cambridge, UK-based biotechnology company, raised £13.7M in Seed funding. The round was led by Epidarex Capital with participation from Dementia Discovery Fund (DDF). Mary Canning, Principal at Epidarex Capital, has... |
| 31.05.2022 | Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development | Cambridge, UK, 31 May 2022: Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, announces that it has successfully raised £4.6 million... |
| 05.07.2021 | Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO | Dr Thirkettle is a seasoned life sciences executive with deep experience and a proven track record in building successful novel platforms |
| 05.07.2021 | Transine Therapeutics appoints industry veteran Jan Thirkettle PhD as CEO | Transine Therapeutics appoints industry veteran Jan Thirkettle PhD as CEO 05-07-2021 Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, today anno... |
| 03.06.2021 | Transine Therapeutics Raises £9.1 in Funding | Transine Therapeutics, a Cambridge UK-based biotechnology company which specializes in development of therapeutic RNAs, closed £9.1 in funding. The round was led by Takeda Ventures, Inc. and the Dementia Discovery Fund (DDF). In conjunction... |
| 02.06.2021 | Transine Therapeutics Closes Extended Seed Funding of £9.1 million co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to advance its novel class of therapeutic RNAs | New Company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression |
| 02.06.2021 | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs | New company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression. Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SI... |
| 02.06.2021 | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs 02-06-2021 New company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression. ... |